MammaPrint® + BluePrint® together help simplify the complexity of early stage breast cancer.
Clear results matterThe genomic insight provided by our tests helps assess the risk of breast cancer recurring.
The data behind our precision approachBacked by the highest level of evidence, our tests are driving the most innovative new studies.
Laura van ’t Veer, PhD, Co-Inventor of MammaPrint, Honored with the PMWC Luminary Award at Precision Medicine World Conference 2020
PRESS RELEASE …
The path to personalized treatmentA breast cancer diagnosis can often mean you are faced with many difficult and unanswered questions. Do I need chemotherapy? What are my options? Can I benefit from a less radical treatment strategy? At Agendia, we believe it’s our collective responsibility to help ease this anxiety with breakthrough genomic testing for breast cancer. Our clinically proven MammaPrint® and BluePrint® tests provide patients with valuable information hidden in the genes of their tumor. They also provide physicians with the genomics data they need to make informed personalized treatment management decisions with confidence.
I am so thankful that I had all the information I needed—thanks to personalized medicine—to make the right decision for me and my particular cancer. I was treated as an individual and not as a disease. — Sara, a breast cancer survivor